Focus: Laekna Therapeutics is a Shanghai-based biotech company developing small-molecule oncology and gastroenterology therapeutics, currently in early-to-mid stage clinical development with a public listing status.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Laekna Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Laekna Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Laekna Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Global Radiopharmaceuticals Market Set for Significant Expansion at a CAGR of ~10% by 2034 with Increasing Adoption of Targeted Radiotherapy | DelveInsight - PR Newswire UK
Global Radiopharmaceuticals Market Set for Significant Expansion at a CAGR of ~10% by 2034 with Increasing Adoption of Targeted Radiotherapy | DelveInsight PR Newswire UK
Platinum-Resistant Ovarian Cancer Treatment Market Gains - openPR.com
Platinum-Resistant Ovarian Cancer Treatment Market Gains openPR.com
Mapping the noteworthy startups in China’s health sector - Tech in Asia
Mapping the noteworthy startups in China’s health sector Tech in Asia
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company